Brawn Biotech Ltd (BRAWN)

Loading page…

Brawn Biotech Ltd (BRAWN) · mywealthgrid

About

Brawn Biotech Ltd operates in Pharmaceuticals within the Healthcare sector.

Face value: ₹10

Market cap

₹7 Cr

P/E

—

P/B

1.7×

Dividend yield

ROE

24.4%

ROCE

Debt / equity

OPM

-1.9%

EPS (TTM)

₹-6.0

Book value

₹14.5

52-week high

—

52-week low

—

2,189 historical price candles were omitted because the exchange source has not been verified.

₹24.6+9.6%1Y

Quick read

rule-based

Pros

+Almost debt-free (debt/equity 0)

Cons

−Low return on equity of -13% (3-yr avg)
−Revenue shrank over the last 5 years (-13.5% a year)

Research score

Structured signal from quality, growth, valuation and momentum.

47/100

Business quality: 44
Growth: 0
Valuation: 97

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore · years without a filed annual are summed from quarters

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	46	60	55	65	50	35	9	22	16	13	17
COGS	-40	-52	-49	-59	-42	30	7	19	14	12	15
Gross profit	—	—	—	—	—	5	2	3	2	2	2
	85	112	103	123	91	6	4	3	4	3	3
	1	0	1	1	1	-1	-2	-0	-2	-2	-0
OPM %	1.1%	0.5%	2.2%	1.7%	1.5%	-1.7%	-23.3%	-1.4%	-9.3%	-13.3%	-1.9%
Depreciation	0	0	—	0	0	0	0	0	0	0	0
Interest	0	0	0	0	0	0	0	0	0	0	0
	—	—	1	1	0	0	0	0	0	0	0
Profit before tax	1	2	2	2	1	-0	-2	-0	-2	-2	0
Tax	—	0	1	0	0	0	-0	0	-0	-0	-1
Tax %	—	20.5%	34.7%	26.7%	29.3%	52.8%	-22.2%	112.2%	-19.5%	-3.3%	—
	1	1	1	1	1	-1	-2	-1	-1	-2	1
PAT margin %	2.1%	2.3%	2.3%	2%	1.2%	-1.6%	-19%	-3.9%	-7.6%	-12.9%	5.5%
EPS (₹)	2	4.6	4.2	4.6	2	-1.6	—	-3	—	—	3.3
EPS adjusted (₹)	—	—	—	—	2	-1.8	-5.5	-2.9	-4.2	-5.8	3.1
	0%	32.3%	23.9%	0%	0%	—	—	—	—	—	—
Annual report	Annual report for Mar 2016	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	3	3	3	3	3	3	3
Reserves	6	6	4	3	2	0	1
Minority interest	—	0	—	—	0	—	—
	—	0	0	0	0	0	0
	11	5	7	8	10	17	17
Total equity & liabilities	20	14	14	15	15	20	21
	0	0	0	0	0	0	0
CWIP	—	—	—	—	—	—	0
Investments	—	0	0	0	0	0	0
	20	14	13	14	14	20	21
Total assets	20	14	14	15	15	20	21

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	0	1	-2	0	-0	0	0	0	-0	0	0
	-0	1	0	0	-0	0	-0	-0	-0	-0	-0
	-0	-0	-0	-0	-0	-0	-0	0	0	0	0
Net cash flow	0	2	-2	0	-0	-0	-0	0	-0	-0	0
Free cash flow	—	—	—	—	—	—	—	0	—	—	0
CFO / Operating profit %	82%	456.7%	-128.3%	18.8%	-10.8%	—	—	—	—	—	—

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	14.2%	23.7%	13.8%	12.9%	11.4%	14.5%
EBITDA margin %	1.7%	1.5%	-1.7%	-23.3%	-1.4%	-9.3%	-13.3%	-1.9%
EBIT margin %	1.7%	1.4%	-1.8%	-23.9%	-1.8%	-9.9%	-14.1%	-2.7%
PAT margin %	2%	1.2%	-1.6%	-19%	-3.9%	-7.6%	-12.9%	5.5%
Working capital
Receivable days	—	110	97	119	87	86	92	76
Inventory days	—	3	3	262	91	153	320	253
Payable days	—	64	32	225	123	144	252	362
NWC days	—	49	68	156	55	95	161	-33
Leverage
Current ratio	—	1.76	2.6	1.93	1.66	2.02	1.88	1.13
Debt to EBITDA	—	—	—	—	—	—	—	—
Debt to equity	—	—	0	0	0	0	0	0
Interest coverage	31	17.6	-8	-34.3	-40	—	—	—
Asset turnover	—	2.45	2.52	0.63	1.53	1.13	0.66	0.81
Return ratios
Return on assets %	—	2.9%	-4%	-11.9%	-6%	-8.6%	-8.5%	4.5%
Return on capital employed %	—	9.4%	-3.5%	-25.1%	-5.7%	-21.3%	-18.7%	0%
Return on equity %	—	6.4%	-6.3%	-22.7%	-13.8%	-24.7%	-51.8%	21.7%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	53.72%	53.72%	53.64%	53.64%	53.64%	53.64%	53.66%	53.66%	53.66%	53.39%	52.94%	52.94%
FII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	0.59%	0.59%	0.35%	0.35%	0.35%	0.35%	0.35%	0.35%	0.35%	0.35%	0.35%	0.35%
	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	45.69%	45.69%	46.01%	46.01%	46.01%	46.01%	45.99%	45.99%	45.99%	46.26%	46.71%	46.71%
No. of shareholders	—	—	—	—	—	—	—	—	3,958	3,444	3,303	3,284

Promoter holding down 0.78 percentage points since Sep 2023.

2 deals · 20 Dec 2024 – 20 Dec 2024

Date	Client	Type	Venue	Side	Quantity	Price	Value
20 Dec 2024	NAIMABBAS ANVARALI JAMANI	Bulk	BSE	Buy	17,650	₹22.76	₹0.04 Cr
20 Dec 2024	NAIMABBAS ANVARALI JAMANI	Bulk	BSE	Sell	2,000	₹22.50	₹0.00 Cr

1–2 of 2

1 / 1

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Amit KumarManager
Brij Raj GuptaDirector
Mr. Mayank JainNon-Executive - Independent Director
Mrs. Pooja JhaNon-Executive - Indepenent Director
Ms. Priyanka SharmaCompany Secretary & Compliance Officer
Mrs. Rati GargChief Financial Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Brawn Biotech Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

2

Final dividend12 Sept 2018 · ex-date₹1
Final dividend14 Sept 2017 · ex-date₹1.5

1

Board meeting to consider results13 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

11 announcementsExport CSV

1 Sept 2026, 4:45 pmAGM/EGM

Notice Of 41St AGM To Be Held On 29.09.2026

AGM PDF

Loading announcements…

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	14.2%	23.7%	13.8%	12.9%	11.4%	14.5%
EBITDA margin %	1.7%	1.5%	-1.7%	-23.3%	-1.4%	-9.3%	-13.3%	-1.9%
EBIT margin %	1.7%	1.4%	-1.8%	-23.9%	-1.8%	-9.9%	-14.1%	-2.7%
PAT margin %	2%	1.2%	-1.6%	-19%	-3.9%	-7.6%	-12.9%	5.5%
Working capital
Receivable days	—	110	97	119	87	86	92	76
Inventory days	—	3	3	262	91	153	320	253
Payable days	—	64	32	225	123	144	252	362
NWC days	—	49	68	156	55	95	161	-33
Leverage
Current ratio	—	1.76	2.6	1.93	1.66	2.02	1.88	1.13
Debt to EBITDA	—	—	—	—	—	—	—	—
Debt to equity	—	—	0	0	0	0	0	0
Interest coverage	31	17.6	-8	-34.3	-40	—	—	—
Asset turnover	—	2.45	2.52	0.63	1.53	1.13	0.66	0.81
Return ratios
Return on assets %	—	2.9%	-4%	-11.9%	-6%	-8.6%	-8.5%	4.5%
Return on capital employed %	—	9.4%	-3.5%	-25.1%	-5.7%	-21.3%	-18.7%	0%
Return on equity %	—	6.4%	-6.3%	-22.7%	-13.8%	-24.7%	-51.8%	21.7%

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Date	Category	Subject	Filing
1 Sept 2026, 4:45 pm	AGM/EGM AGM	Notice Of 41St AGM To Be Held On 29.09.2026	PDF
14 Aug 2026, 11:39 am	Company Update Newspaper Publication	Announcement under Regulation 30 (LODR)-Newspaper Publication	PDF
8 Jul 2026, 3:49 pm	Company Update Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018	PDF

Brawn Biotech Ltd

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

2

1

Announcements

Not in the F&O segment

2

1

No fund holdings on record

Announcements

Annual reports

Compounded sales growth

Compounded profit growth

Return on equity

Brawn Biotech Ltd

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

Dividends2

Board meetings1

Announcements

Ratio timeline

Not in the F&O segment

Dividends2

Board meetings1

Quarterly record

Bulk & block deals

Board and management

No fund holdings on record

Announcements

Annual reports

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

2

1

2

1